Equine/Horse Herpesvirus glycoprotein D antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Equine/Horse Herpesvirus glycoprotein D antibodies pairs and antigen for animal health (animal Equine/Horse infectious disease Equine/Horse Herpes Myeloencephalopathy) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Equine/Horse disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P136-Tg001-Ag01	Recombinant Equine/Horse Herpesvirus glycoprotein D protein	$3090.00
GMP-VT-P136-Tg001-Ab01	Anti-Equine/Horse Herpesvirus glycoprotein D mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P136-Tg001-Ab02	Anti-Equine/Horse Herpesvirus glycoprotein D mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P136-Tg001-Ab03	Anti-Equine/Horse Herpesvirus glycoprotein D human monoclonal antibody (mAb)	$3090.00
GMP-VT-P136-Tg001-Ab04	Anti-Equine/Horse Herpesvirus glycoprotein D human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P136-Tg001-Ag01
Product Name	Recombinant Equine/Horse Herpesvirus glycoprotein D protein
Pathogen	Equine/Horse Herpesvirus
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine/Horse Herpesvirus glycoprotein D antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Equine/Horse Herpesvirus level test of animal Equine/Horse infectious disease with Equine/Horse Herpes Myeloencephalopathy.
Tag	His
Product description	Recombinant Equine/Horse Herpesvirus glycoprotein D proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P136-Tg001-Ab01,GMP-VT-P136-Tg001-Ab02
Pathogen	Equine/Horse Herpesvirus
Product Name	Anti-Equine/Horse Herpesvirus glycoprotein D mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine/Horse Herpesvirus glycoprotein D antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus antibodies in Equine/Horse Herpesvirus level test of animal Equine/Horse infectious disease with Equine/Horse Herpes Myeloencephalopathy.
Product description	Anti-Equine/Horse Herpesvirus glycoprotein D mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P136-Tg001-Ab03,GMP-VT-P136-Tg001-Ab04
Pathogen	Equine/Horse Herpesvirus
Product Name	Anti-Equine/Horse Herpesvirus glycoprotein D human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Equine/Horse Herpesvirus glycoprotein D antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus antibodies in Equine/Horse Herpesvirus level test of animal Equine/Horse infectious disease with Equine/Horse Herpes Myeloencephalopathy.
Product description	Anti-Equine/Horse Herpesvirus glycoprotein D mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Equine Herpesvirus (EHV): A Comprehensive Overview

Equine Herpesvirus (EHV), a member of the Herpesviridae family, is a complex, double-stranded DNA virus with profound implications in equine health. Understanding this pathogen's characteristics, classification, structure, associated diseases, and diagnostic methods is vital for veterinarians, horse owners, and researchers.

Classification and Structure:

EHV is classified as a eukaryotic virus, distinguishing it from prokaryotic entities such as bacteria. Within the viral realm, EHV belongs to the Herpesviridae family, a diverse group of enveloped, large DNA viruses known for their ability to infect a wide range of hosts, including humans and various animal species.

At its core, EHV's structure is multifaceted, reflecting its intricate genetic composition. The virus encodes an array of genes, among which glycoproteins, notably glycoprotein B, play a pivotal role in the virion's structure. These glycoproteins are essential for viral entry and cell-to-cell spread within the host. In addition to structural proteins, EHV genes include enzymes necessary for viral replication and transcription.

Hosts Infected and Associated Diseases:

EHV primarily targets equine species, encompassing horses, donkeys, and mules. Within this host spectrum, two specific types of EHV are of paramount importance:

EHV-1 (Equine Herpesvirus 1):

EHV-1 is associated with a wide range of clinical conditions in horses. It can cause:

Respiratory Disease: EHV-1 often initiates as a respiratory infection, leading to clinical signs such as nasal discharge, coughing, and fever.

Reproductive Complications: Pregnant mares infected with EHV-1 are at risk of abortion, stillbirth, or the birth of weak foals.

Neurological Afflictions (EHM): Perhaps the most concerning aspect of EHV-1 infection is its potential to cause Equine Herpesvirus Myeloencephalopathy (EHM). This condition manifests as a severe neurological disease and can lead to ataxia, hind limb weakness, and even death in affected horses.

EHV-4 (Equine Herpesvirus 4):

EHV-4 predominantly induces respiratory disease in horses, often resulting in clinical signs like coughing, nasal discharge, and fever. While less likely to lead to the severe complications seen with EHV-1, EHV-4 can still cause economic and health burdens through reduced performance and treatment costs.

Diagnostic Methods:

Diagnosing EHV necessitates a multifaceted approach, integrating clinical evaluation, laboratory analysis, and sophisticated molecular techniques, notably involving nucleic acid detection. Key diagnostic methods include:

Polymerase Chain Reaction (PCR): PCR assays are a cornerstone of EHV diagnostics. They allow for the detection and genetic characterization of the virus. By targeting specific nucleic acid sequences unique to EHV, PCR enables definitive identification in equine clinical samples.

Virus Isolation: Equine Herpesvirus can be cultivated and isolated from biological specimens, such as nasal swabs, using cell culture techniques. This method facilitates the characterization of viral isolates and provides valuable insights into strain variability.

Serology: Serological assays assess the presence of antibodies against EHV in equine blood samples. The detection of antibodies signifies previous exposure or active infection, aiding in epidemiological investigations.

In conclusion, Equine Herpesvirus (EHV) is a multifaceted pathogen with significant implications for equine health. Its classification as a member of the Herpesviridae family, complex genetic structure, and the potential to cause a range of clinical conditions underscore the importance of accurate diagnostics and robust preventive measures within the equine industry. Veterinary professionals, horse owners, and researchers must remain vigilant and well-informed about EHV to mitigate its impact on equine populations.

For the most contemporary and precise information concerning Equine Herpesvirus and its diagnostic methodologies, consultation with veterinary professionals and diagnostic laboratories specializing in equine virology is recommended, as advancements in the field may have transpired since my last knowledge update in September 2021.

About GDU